O'Brien et al. (2022) noted that elevated lncRNA H19 expression affects the KRAS mutation status and increases the risk of distal metastasis in COAD patients, and H19 could be a potential molecular biomarker for the prognosis and treatment of COAD. Cuproptosis is a newly discovered mode of cell death, and given the role of copper homeostasis in cancer progression and copper complexes as potential therapeutic options (Tsvetkov et al., 2022; Li, 2020; da Silva et al., 2022), this report is the first to screen prognostic CRLs in COAD via a bioinformatics approach. The gene discussed is KRAS; the disease is cancer.